Curaleaf Holdings Earnings Call Signals Cautious Upswing

Curaleaf Holdings (OTC) ((TSE:CURA)) has held its Q1 earnings call. Read on for the main highlights of the call.

Curaleaf Holdings’ latest earnings call struck a cautiously optimistic tone, as management balanced solid revenue growth and a swing to profitability against ongoing margin pressure and market headwinds. Executives emphasized operational improvements, international momentum, and powerful regulatory catalysts that they believe will unlock substantial upside over the next few years.

Revenue Growth Beats Expectations

Curaleaf reported Q1 2026 revenue of $324 million, up 6% year over year and above prior guidance, though down 3% sequentially on typical seasonality. Management guided to Q2 revenue growth of 2% to 3% quarter over quarter, implying around $333 million at the midpoint and signaling confidence in demand trends despite a mixed macro backdrop.

International Outperformance Leads the Story

International operations were a clear standout, with Curaleaf International revenue climbing 35% year over year and outpacing the domestic business. Management highlighted strong momentum in Germany and the U.K., noting that overseas performance exceeded internal plans and is increasingly central to the company’s long‑term growth thesis.

Profitability Turns Sharply Positive

The company delivered a significant swing in profitability, posting net income from continuing operations of $70 million, or $0.09 per share, versus a $50 million loss, or −$0.09 per share, a year earlier. This marks a notable shift from loss‑making to profitable, even as Curaleaf continues to invest heavily in growth and navigates price and cost pressures in key markets.

Adjusted EBITDA and Gross Margin Remain Solid

Adjusted EBITDA came in at $63 million, representing a 20% margin that remains healthy for a growing cannabis platform despite modest year‑over‑year slippage. Gross profit reached $157 million for the quarter, translating to a 49% gross margin that management believes can improve over time as international operations scale and cost initiatives take hold.

Wholesale and Retail Execution Diverge

Domestic wholesale grew 19% year over year, underscoring the strength of Curaleaf’s brand and distribution relationships even in competitive markets. In Florida, retail transaction counts rose about 15% year over year after product and assortment changes, helping offset price compression that continues to weigh on average ticket sizes and overall retail revenue.

Balance Sheet and Financing Strengthen

Curaleaf ended the quarter with $106 million of cash and continued to chip away at acquisition‑related debt, reducing it by $9 million. The company also refinanced a $475 million senior secured note with an oversubscribed $500 million three‑year facility, a move that extends maturities and signals a vote of confidence from credit investors.

Strategic International Consolidation in Germany

Management underscored the strategic importance of completing the buyout of the remaining 45% minority interest in German subsidiary Four 20 Pharma, giving Curaleaf International full ownership. The transaction implied a roughly $1 billion valuation for the international business, highlighting the perceived value of the company’s European footprint as medical markets evolve.

Rescheduling Offers Powerful Regulatory Tailwind

Executives pointed to U.S. federal rescheduling of medical cannabis from Schedule I to Schedule III as a potential game‑changer for the business. They see material upside from prospective relief on punitive tax treatment that has historically constrained earnings, as well as better access to banking, credit, and research opportunities as regulations modernize.

Operational and Product Initiatives Support Demand

Curaleaf continued rolling out its Built for Growth playbook, focusing on customer centricity, operational excellence, and brand building across markets. New offerings such as BRIC 2 and Dark Heart ultra‑premium flower are aimed at stabilizing pricing and driving higher units and traffic, particularly in mature states where discounting remains a challenge.

Audit and Governance Upgrades Ahead of Uplisting Hopes

The company transitioned its independent audit partner to BDO, a move framed as part of broader efforts to enhance transparency and governance. Management linked this upgrade to long‑term aspirations of eventually uplisting to a major U.S. exchange once regulatory conditions allow, positioning Curaleaf for a broader investor base.

Sequential Revenue Dip Reflects Seasonality

Despite the upbeat top‑line growth versus last year, revenue fell 3% sequentially compared with Q4 2025. Leadership attributed the decline largely to normal seasonality rather than structural demand issues, suggesting that the underlying growth trajectory remains intact heading into the typically stronger middle quarters of the year.

Gross Margin Compression Weighs on Results

Overall gross margin contracted by 220 basis points year over year, reflecting a tougher pricing environment and international growing pains. International gross margin landed at 42% and declined 190 basis points sequentially, pressured by pricing in the U.K., weaker German flower performance, and lower contributions from higher‑margin services.

Adjusted EBITDA Faces International Drag

Adjusted EBITDA decreased 4% year over year, and the adjusted EBITDA margin fell 200 basis points as investments in international expansion weighed on profitability. Management said international initiatives alone created a 170 basis point drag on margin, arguing that these costs are front‑loaded and should normalize as overseas volumes scale.

Rising SG&A Reflects Growth Investments

SG&A expenses increased to $113 million, up $7 million from a year ago, with core SG&A at $108 million, up $5 million year over year. The company pointed to international expansion, higher headcount, and new store openings as the main drivers, positioning the spending as necessary to support long‑term revenue growth and brand strength.

Working Capital and Cash Flow Remain Tight

Inventory rose by $16 million, or 7% sequentially, as Curaleaf built stock ahead of upcoming product launches, which in turn constrained near‑term cash generation. The company generated $21 million in operating cash flow and $4 million in free cash flow for Q1, while reiterating a full‑year capital expenditure plan of roughly $80 million.

Market and Geographic Headwinds Persist

Domestic performance remained uneven, with weaknesses in Nevada and Illinois offsetting stronger results in other states, highlighting the patchwork nature of U.S. cannabis markets. Price compression and discounts continue to weigh on several regions, though management noted early signs that the pace of price erosion is starting to slow.

International Supply Chain Friction

Curaleaf acknowledged transitional challenges in its international supply chain that pressured margins in the quarter, particularly around sourcing and logistics. These dynamics have prompted a reassessment of planned capital spending for international cultivation expansion, as the company looks to optimize its asset base and protect returns.

Regulatory and Policy Unknowns Temper Enthusiasm

While rescheduling is a major positive, management cautioned that key policy questions remain unresolved, including the scope and timing of potential tax relief and licensing benefits. They also flagged uncertainty around the policy timeline for broader financial reforms and potential legal and political risks associated with evolving hemp‑related regulations.

Macro Sensitivities Could Impact Demand

Executives noted that inflationary pressures and higher energy prices can squeeze consumer wallets, potentially limiting discretionary spending on cannabis products. This macro risk adds another layer of uncertainty to near‑term demand trends, even as regulatory and structural drivers remain positive for the sector over the longer term.

Forward‑Looking Guidance and Expectations

For Q2, Curaleaf expects revenue to grow 2% to 3% sequentially from Q1’s $324 million, targeting roughly $333 million at the midpoint. Management reaffirmed full‑year capital expenditures of about $80 million and projected operating cash flow to build as 2026 progresses, supported by strong international growth of roughly 25% to 30%, continued wholesale momentum, and anticipated tax and financing benefits from regulatory changes.

Curaleaf’s earnings call painted a picture of a company at an inflection point, with solid top‑line growth, a return to net profitability, and powerful regulatory tailwinds offset by margin compression and uneven market conditions. For investors, the key narrative is whether international expansion and regulatory relief can outpace ongoing pricing and cost pressures, potentially unlocking meaningful upside in the quarters ahead.